REBEAT Resynchronisation and Beta-Blocker European Trial

This study has been terminated.
(lack of enrolment)
Sponsor:
Information provided by:
Guidant Corporation
ClinicalTrials.gov Identifier:
NCT00305526
First received: March 21, 2006
Last updated: August 8, 2007
Last verified: August 2007
  Purpose

This protocol will evaluate the effect of cardiac resynchronization therapy (CRT) combined with beta-blocker therapy in patients with symptomatic heart failure in whom beta-blocker therapy was either not tolerated or could not be up titrated to optimal doses before CRT. Cardiac resynchronization therapy will be combined with automatic implantable cardioverter defibrillator (AICD, CRT-D) as it has been shown to be associated with an improvement in prognosis in the patients with left ventricular systolic dysfunction and heart failure.


Condition Intervention Phase
Heart Failure
Device: Contak Renewal (CRT-D)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: Resynchronisation and Beta-Blocker European Trial

Resource links provided by NLM:


Further study details as provided by Guidant Corporation:

Primary Outcome Measures:
  • LVEF changes between baseline and 6 months measured by Echocardiography

Secondary Outcome Measures:
  • increase % of patients with successful uptitration for Betablockers, reduce all cause hospitalizations and all cause mortality, reduce all cause mortality and heart failure hospitalizations, reduce all cause mortality and cardiovascular hospitalizations

Estimated Enrollment: 354
Study Start Date: April 2006
Study Completion Date: July 2007
Detailed Description:

The purpose of this investigation is to evaluate the effect of CRT combined with beta-blocker therapy in patients with symptomatic heart failure in whom beta-blocker therapy was either not tolerated or could not be up-titrated to optimal doses before CRT.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Symptomatic heart failure and indication for cardiac resynchronization therapy (CRT), Hemodynamic stability with documented intolerance to beta-blocker therapy or treatment with beta-blocking agents at sub-optimal dosages (<25% of optimal dosage).

Exclusion Criteria:

  • chronic atrial fibrillation; indications for permanent antibradycardia pacing; mechanical tricuspid valve; Severe aortic stenosis or other primary valve disease causing cardiomyopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00305526

Locations
Italy
Spedali Civili di Brescia
Brescia, Italy, 25100
Istituto clinico Humanitas
Milano, Italy
Switzerland
Cardiocentro Ticino
Lugano, Switzerland
Sponsors and Collaborators
Guidant Corporation
Investigators
Principal Investigator: Antonio Curnis, MD Spedali Civili di Brescia, Brescia, Italy
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00305526     History of Changes
Other Study ID Numbers: REBEAT 1.5
Study First Received: March 21, 2006
Last Updated: August 8, 2007
Health Authority: Italy: Ministry of Health

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 24, 2014